Roivant Sciences Ltd.
NASDAQ: ROIV0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- NASDAQ Global Market
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Matthew Gline
- Employees
- 908
- Headquarters
- London, United Kingdom
- IPO year
- 2020
- Market cap
- $22.6B
- Website
- https://roivant.com
Loading ROIV…
Loading profile data…Frequently asked questions about ROIV
What does Roivant Sciences Ltd. (ROIV) do?
Roivant Sciences Ltd. is a biopharmaceutical and healthcare technology company dedicated to discovering and advancing innovative therapeutic drugs. The firm's development pipeline targets a broad spectrum of diseases, including various forms of solid tumors and oncologic malignancies, hematological disorders like sickle cell disease and warm aut...
Where does ROIV trade?
Roivant Sciences Ltd. (ROIV) trades on the NASDAQ Global Market.
What sector is ROIV in?
Roivant Sciences Ltd. (ROIV) operates in the Healthcare sector, specifically in the Biotechnology industry.
Who is the CEO of Roivant Sciences Ltd.?
Matthew Gline is the chief executive officer of Roivant Sciences Ltd. (ROIV).
Where is Roivant Sciences Ltd. headquartered?
Roivant Sciences Ltd. is headquartered in United Kingdom.
Does ROIV pay a dividend?
Roivant Sciences Ltd. (ROIV) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did ROIV go public?
Roivant Sciences Ltd. (ROIV) completed its initial public offering in 2020.